News and Trends 21 Feb 2017 A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa Apitope is developing therapeutic peptides to induce suppression of autoimmune responses towards self-antigens. Their recent phase IIa trial has revealed promising results for the treatment of multiple sclerosis. Multiple sclerosis… February 21, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 Scancell in-licenses Vaccitech’s SNAPvax tech for cancer study Scancell Holdings plc, a developer of immunotherapies, today (November 7) announced it has in-licensed the SNAPvax technology from Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development… November 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2022 Amphista Lands Megadeals to Smash Cancer using Protein Degradation As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb… May 5, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2018 This British Liquid Biopsy Could Save Us $5000 per Prostate Cancer Patient ANGLE’s liquid biopsy technology measures the expression of an important prostate cancer biomarker, helping to identify the best treatment for different groups of patients. ANGLE is a world leader in… January 8, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2018 Gene Therapy Company’s IPO Shoots it to Billion-Euro Biotech List Orchard Therapeutics, a British company developing gene therapy for rare genetic diseases, has launched its Nasdaq IPO and is now reportedly worth $1.25B (€1B). This IPO propels Orchard to the… November 1, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 6 Aug 2024 The biggest private biotech investments in July 2024 The companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest private biotech investments in July 2024. Around the world, oncology and central nervous system players attracted the… August 6, 2024 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2021 UK Startup Surfs Investment Wave in Microbiome with €18M Series A As increasing attention turns to microbiome-based therapeutics, the Scottish biotech Enterobiotix has closed a Series A fundraising to potentially treat a myriad of medical conditions by improving gut health. Last… September 15, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 PolyPid to receive millions for commercialization of infection-fighting drug A drug to prevent surgical site infections (SSIs) in abdominal and cardiac surgeries in Europe is to be commercialized after two companies entered an exclusive licensing agreement. Israel-based PolyPid Ltd… August 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jun 2022 Spirea raises £2.4M to develop antibody drug conjugates in cancer Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to advance a new generation of antibody drug conjugate (ADC) therapeutics. The company will use the… June 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Deep Science Ventures and AbbVie to create companies to target inflammatory diseases Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global pharmaceutical company, to build one or more new companies targeting immune-mediated inflammatory diseases. Together, the… November 28, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval Update (24/10/2017): Shingrix has been approved by the FDA and will cost $280 (€238) for the required two shots, which should be covered by most insurance plans. Originally published on… October 24, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 19 Jul 2019 UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech The UK-based venture capital investment firm Medicxi has closed its third fund, totaling €400M, to nurture early- and late-stage healthcare biotech companies in Europe. The firm will begin investing in… July 19, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email